Redeye reviews the case of Herantis in the wake of progress with clinical candidate HER-096 and H2 report last week.
Redeye endorses the recent news that Herantis has completed a directed issue of EUR4.
Redeye is positive towards the top-line data from the phase Ia trial with HER-096 presented by Herantis.
Redeye endorses today’s news that Herantis has presented positive phase Ia data with HER-096, and the company states that “The clinical tria...
Redeye endorses yesterday’s news that Business Finland has waived-off around EUR4.
Redeye reviews the case of Herantis in the wake of progress with clinical candidate HER-096 and H1 report.
Redeye endorses today’s news that the first healthy volunteers have been dosed in the second part of the phase Ia trial with HER-096.
Redeye is encouraged to learn that the first healthy volunteer has been dosed in the company’s phase Ia trial (n=60) with HER-096.
Redeye endorses today’s news that Herantis has signed the grant agreement with the European Innovation Council (EIC) Accelerator.
Redeye returns with a research update following Herantis H2 report.
Redeye endorses today’s news that Herantis has received approval to start its phase I study with HER-096 in healthy volunteers.
Redeye revisits its view of Herantis in the wake of the company’s shifted strategy toward HER-096– an engineered derivative of its previous ...
Redeye endorses today’s news that Herantis has submitted a clinical trial application for a phase I study with its lead candidate HER-096 ta...
Redeye comments on yesterday’s H1 report from Herantis and we reiterate our view of the company.
Redeye has a positive take on the news that Antti Vuolanto, currently COO, has been named as CEO of Herantis.
Redeye comments on the recent news in the company and adjust for the recent capital injections in the company.
Redeye comments on the news that Herantis has carried out a directed issue and announced the intention to carry out a rights issue worth in ...
Redeye comments on the H2 report from Herantis Pharma and reiterate our view of the company.
Redeye comments on yesterday’s directed share issue of EUR 4 million.
Summary of events in H1’21 Updated model following refocusing on CNS Upcoming milestones During H1’21, Herantis decided to focus all resourc...
Redeye comments on the H1 report from Herantis Pharma.
